Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine a recommended phase II dose (RP2D).
The secondary objective of the study are:
1. To evaluate preliminary incidence and duration of clinical benefits as determined by
improvements of pain, PSA decline and bone scan changes.
2. To evaluate the toxicity profile of the escalating doses of Docetaxel in combination
with Samarium 153 in patients with advanced, hormone refractory prostate cancer
metastatic to the bone.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins